TECHNICAL APPENDIX
Parameters related to the incidence of glaucoma are detailed in Table 1 . Age influenced 2 important variables: (1) the incidence of POAG, and (2) the proportion of people treated based on the treatment threshold. In both cases, this was because age is a risk factor for progression to glaucoma. The age-specific parameters for progression and proportion of people treated are detailed in Table 1 . The methods used to estimate the incidence and proportion treated are detailed later in this eAppendix. The column titled "Persons, No." indicates the number of people in the OHTS observation group who fell into this category and was used to estimate the standard deviation of the parameter (ie, the binomial estimate of variance: [pϫ (1−p)]/n, where p is the proportion in question and n is the sample size from which the proportion was estimated).
The parameters of the model are detailed in Table 1 of this Appendix. Table 1 includes the variable name of the parameter, a description, and the formula used to calculate the value of the parameter in the model (also included in Table 1 is information related to the Monte Carlo simulation and the sensitivity analysis that will be addressed later). The formulas reference keywords that are used in TreeAge Pro 2005 release 1.1 software (TreeAge Software, Inc, Williamstown, Massachusetts). The keyword DistSamp indicates that the value used in the model comes from a defined distribution. In the point estimate of cost-effectiveness, the value used would be the mean of the distribution (indicated in Table 1 as the value in the model). The keyword UtilDiscount indicates the discounting function used by the TreeAge Pro 2005 software. The 3 arguments enclosed indicate (in order) the parameter to be discounted, the discount rate (3% in the base model), and the periods to be used for discounting (_stage in this case). The keyword _stage indicates the Markov cycle, in this case 1 year. A copy of the decision tree (in TreeAge Pro 2005 format) is available by request to kymes@vrcc.wustl.edu.
ESTIMATING POAG INCIDENCE AND PROPORTION OF PERSONS TO BE TREATED AT EACH THRESHOLD
The incidence of POAG in the treated and untreated groups and the proportion of persons to be treated at each treatment threshold (those with a Ն5%, Ն4%, Ն3%, and Ն2% annual risk of developing glaucoma) were estimated from the OHTS data. A logistic regression model was constructed, incorporating parameters previously reported by OHTS investigators as predictive of POAG in the proportional hazards model: age, central corneal thickness, baseline intraocular pressure, and baseline vertical cup-disc ratio. 1 The predicted probabilities of POAG were estimated in the model for each OHTS observation participant, stratified by age (40-49, 50-59, and 60-69 years), and graphed. Log-normal, ␥, ␤, and normal distributions were tested against the distribution using SAS PROC CAPABILITY (SAS version 8 statistical software; SAS Institute, Inc, Cary, North Carolina). The log-normal distribution was determined to have the best fit. Using this distribution, the cumulative distribution function was estimated for x Ն .05 and xՆ.02 (where x indicates the probability of developing POAG during the study period). This estimate represented the proportion of persons in each age group with intraocular pressure greater than 24 mm Hg who were to be treated if that treatment threshold was chosen. The incidence of POAG among those treated and those untreated was estimated in a distribution-free manner. For those to be treated, the incidence of POAG (prior to medical treatment) was estimated as the mean probability of POAG for those with a predictive probability of disease greater than the threshold (thresholds being .05 and .02). The incidence of POAG for those not treated was the mean probability of those with a predictive probability of POAG less than the threshold.
AGING OF THE COHORT
As age is associated with risk of glaucoma 1 10 , or 0.94%. Mortality changed on an annual basis with the estimated age-specific death rate taken from US census life tables. 4 In running the model, Markov cycles were continued until all people in the hypothetical cohort model had died (56 years). 
ESTIMATING THE PROGRESSION OF POAG
Lee et al 5 reported that 25% of participants in a longitudinal study of the cost of treatment of POAG progressed at least 1 modified Hodapp-Anderson-Parrish stage over 5 years. Assuming a linear temporal relationship, this would indicate that there is a 5% annual risk of progression. The investigators reported that progression to stage 4 or 5 was less frequent than early stages; however, we deemed this nonmaterial given the low rate of progression to stages 4 and 5 in our model. The Advanced Glaucoma Intervention Study trial that enrolled people with more severe disease than considered in our model reported a 3% annual probability of loss of 3 lines of vision as well as a 3.5% annual probability of a 4-point loss of visual field on a 20-point scale. 6 If we assume a direct relationship between the Advanced Glaucoma Intervention Study scale and the Hodapp-Anderson-Parrish stages, this would imply an annual progression of 3.5%; however, this results in an estimated incidence of blindness that nears 0 and is not consistent with epidemiological evidence; therefore, we opted for the estimate by Lee and colleagues.
ESTIMATING THE ANNUAL RISK OF BLINDNESS
Hattenhauer et al 7 found a 20-year probability of blindness (defined as best-corrected visual acuity of Յ20/ 200) in at least 1 eye of 27%. We converted this to an annual probability by dividing by 20, resulting in an annual probability of 1.35%. In the model, we only considered the possibility of bilateral blindness after a patient went blind in 1 eye. Hattenhauer and colleagues found that 9% of people in their cohort progressed to bilateral blindness. Thus, one-third of people who develop unilateral blindness will develop bilateral blindness in 20 years. If the risk of bilateral blindness in people with unilateral blindness is 33% over 20 years, this would translate to a risk of 1.65% annually.
ESTIMATING THE COST OF MEDICAL TREATMENT
At each OHTS visit, the type and quantity of medication given to the patient were recorded for each eye. Data from 8 years of semiannual visits among each medication group were used to estimate the annual cost of medication for the model. Medication use per eye was calculated based on the manufacturer's recommended dosage. The number of drops of medication available per milliliter was estimated based on data from Fiscella et al. 8 The number of bottles of medication required to treat was calculated using the least expensive packaging option and extended using 2005 average wholesale price. 9 Generalized increase in the cost of medication due to price inflation was not considered in this model as we assumed that inflation would affect all cost components equally. 10 A market basket estimate of the cost of medication was created by dividing the number of prescribed medications by the number of participants in the OHTS medication arm. As the shape of the market basket changed from year to year (with shift from ␤-blockers to prostaglandins), we took the average cost of treatment over the 9 years of OHTS data to account for this change. In calculating the cost of treatment, we did not consider the possibility of using generic medications; thus, the cost effect of shifting from generic ␤-blocker to a more expensive prostaglandin was not considered. This also implies that our estimate of the cost of medication is very conservative (ie, more expensive than is likely to actually be seen). The probability of adding a second medication to the treatment regimen was estimated by calculating the average number of medications used by OHTS medication participants. In year 8 of the OHTS trial, this was 1.43 medications. On an annualized basis, this would imply that there is approximately a 4.8% probability of adding a second medication to the regimen. While average wholesale price is often used as the standard to evaluate the cost of medical treatments, 10 some authors have argued that it overestimates the cost of medication. Therefore, the Veterans Administration contract price 11 was used to set the lower boundary for sensitivity analysis.
It was assumed that, on average, 1 additional office visit would be required per year for the patient's entire remaining lifetime to manage medication (until the patient progressed to POAG, at which time the treatment protocol would follow clinical guidelines for people with POAG). This was based on American Academy of Ophthalmology guidelines 12 and expert opinion. The charge for this office visit was based on the Medicare allowable amount. 10 We considered the cost to the patient or informal caregiver in terms of travel and lost productivity following the example by Lairson et al. 13 As noted in the main article, the cost of treatment of POAG was taken from the work by Lee et al. 5 The reader is referred to the article for the details of these estimates.
CATARACT SURGERY AS A COMPLICATION OF MEDICAL TREATMENT OF OCULAR HYPERTENSION
The Barbados Eye Studies 14 found a significant increase in the incidence of nuclear opacities among people treated with intraocular pressure-lowering medication. A similar increase was found in the Early Manifest Glaucoma Trial. 15 Prior to 2003, the OHTS did not assess participants for the presence or degree of nuclear opacities, but a nonsignificant increase in the incidence of cataract surgery was found between those randomized to treatment and the observation. This increased absolute risk (0.33% on an annual basis) is included in the model as a risk experienced by all those receiving medical treatment for ocular hypertension. However, we did not include this as a risk for people treated for glaucoma. There have been no reported estimates of this risk, and if there is a risk it arguably is experienced by all people with glaucoma. Thus, it would not represent an incremental risk associated with treatment of people with ocular hypertension.
The cost of cataract surgery and the utility loss associated with having an untreated cataract were taken from an article by Busbee et al. 16 Like Busbee and colleagues, we recognize the loss of utility as a one-time event experienced in the year in which the cataract is extracted. This method does not reflect the possibility of incremental loss of utility associated with the development of a nuclear opacity over preceding years, and thus it is likely to underesti-mate the total utility loss due to cataract progression and to lead to an overestimation of the cost-effectiveness of treatment, particularly if our estimate of the increased risk of cataract associated with treatment is underestimated as well. We examined this question in 2-way sensitivity analysis and found that even if we doubled the estimate of utility loss to 0.25, we would need to increase the risk of cataract surgery by nearly 10-fold before treatment of people with a 2% or greater annual risk of POAG would not be costeffective compared with the threshold of a 5% or greater annual risk. Thus, this weakness in the estimate of utility loss is not likely to introduce substantial error into the costeffectiveness decision.
COST ASSOCIATED WITH BILATERAL BLINDNESS
As noted in our article, Meads and Hyde 17 summarize a number of reports on costs associated with blindness due to a number of conditions. The annual cost of blindness associated with each condition is detailed in Table 2 . Using a conversion rate of US $1.861 per £1 to convert to US dollars, taking the average of these estimates yields an average annual cost of blindness of US $8130.
It is a limitation of each of these estimates that they include social transfer payments (ie, welfare disability payments) as a substantial component. Such payments represent not an actual consumption of social resources but a transfer of wealth from one member to another. For that reason, such payments should not be included in an economic evaluation. 10 However, these estimates do not include the substantial indirect costs associated with blindness (ie, burden on family members, lost productivity, increased use of public transportation, etc); therefore, we made the assumption that these estimates provide a reasonable proxy estimate of the total economic social burden of blindness.
UTILITY LOSS DUE TO POAG
There are 2 articles by Jampel et al 23, 24 concerning the utility loss associated with POAG using the same sample. Jampel and colleagues reported that in a clinic-based cohort, there was an average utility loss of 0.061 among people with glaucoma and suspected glaucoma. When glaucoma and suspected glaucoma were stratified, they found a utility loss of 0.026 associated with suspected glaucoma and 0.07 associated with glaucoma. However, the estimate for suspected glaucoma was not stratified by stage of disease.
Alm et al 25 reported utility losses of 0.16 in stage 1, 0.20 in stages 2 to 4, and 0.28 in stage 5 (approximately unilateral blindness). These were based on the EQ-5D 26 and clearly represent a perception of much more severe disease than that found by Jampel and colleagues. Using the standard gamble, Lee et al 27 reported a utility loss of 0.076 associated with living with ocular hypertension, 0.112 for conditions roughly comparable to Hodapp-AndersonParrish stages 1 and 2, and 0.143 for conditions comparable to Hodapp-Anderson-Parrish stages 3 and 4.
From this, we selected the most conservative estimates that we deemed solidly grounded in theory. We argue that suspected glaucoma in the articles by Jampel and colleagues represents ocular hypertension; therefore, we used this estimate (0.026) to represent the utility loss associated with stage 1 glaucoma. The estimate from Lee and colleagues for stages 1 and 2 (0.112) was used for stages 2 and 3, and the estimate for stages 3 and 4 (0.143) was used for stages 4 and 5. While these estimates may not represent the true estimate of utility loss associated with the progression of glaucoma, it does represent a more conservative estimate of utility loss than that reported by Alm and colleagues.
DETERMINING THE EFFECT OF LIFE EXPECTANCY ON COST-EFFECTIVENESS
We exogenously set a cohort's life expectancy by first assigning the Markov termination condition equal to a variable in the TreeAge Pro 2005 software entitled LifeExpectancy. Then, a 1-way sensitivity analysis was performed where LifeExpectancy varied from 1 through 56. TreeAge then output the expected costs and benefits of each treatment threshold-life expectancy pair for a particular age cohort. Because we tested 5 treatment thresholds (in those with a Ն5%, Ն4%, Ն3%, and Ն2% annual risk of developing glaucoma and treating no one until there is evidence of glaucoma-related nerve damage) and there are 56 different possible life expectancies, 224 different cost and benefit calculations were calculated for each age cohort. Costs and benefits from each of the treatment thresholds when treatment was administered (the thresholds of treating those with a Ն5%, Ն4%, Ն3%, and Ն2% annual risk of developing glaucoma) were then compared with the costs and benefits from the threshold of treating no one to calculate an incremental costeffectiveness ratio (ICER) for each treatment-life expectancy-age cohort combination:
where i equals the life expectancy of a person; j, the treatment threshold; and k, a particular age cohort. j=0 implies the treatment threshold of treating no one. The ICER ijk value was then compared with 1 of 3 standard WTP thresholds ($50 000, $75 000, and $100 000). The value of i from the first ICER ijk (which varied from i=1 to i=56) that fell under the WTP thresholds was recorded as the minimum length of life that a person with treatment threshold j and age cohort k would need for treatment to be cost-effective at that particular WTP threshold. 
DETERMINING COST-EFFECTIVENESS FOR PARTICULAR AGE COHORTS
Simple cost-effectiveness outputs for each age cohort (ages 45, 55, and 65 years) were determined from the costeffectiveness analysis command in TreeAge. The ICERs from this command were again compared with the 3 standard WTP thresholds, and the first treatment threshold to fall under that WTP threshold was identified as the least restrictive treatment that could be administered and still be cost-effective. These ICERs were calculated by comparing the costs and benefits for a particular treatment group with the next least costly treatment group for a particular age cohort.
